Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

ng tax related to the Servier transaction and the non-recurring payment to Celera in accordance with the Servier transaction. We believe the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that. Presently, Pharmacyclics has 4 product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecule
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
(Date:11/24/2014)... Nov. 24, 2014  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 3, 2014 at The New ... . A live webcast of the Company,s presentation ... feature an overview of the company by Pat Mackin ...
(Date:11/24/2014)... Colo. , Nov. 24, 2014 ... Inc. (NYSE MKT: AMPE), today announced the presentation ... RedoxSYS™ Diagnostic System as a broadly applicable and ... (ORP) in the body in response to injury, ... were performed in collaboration with Luoxis, academic and ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... ISI Telemanagement Solutions, Inc., a leading ... the 2014 Lync Pioneer Award by ... a great honor to ISI, who continues to ... ISI offers an integrated collaboration reporting and recording ... voice, video, Lync IM, and conferencing. , ...
(Date:11/26/2014)... For those with a New Year’s resolution to get in ... at the University of Colorado Anschutz Health and Wellness Center ... 45- 60 minute classes have just started and are included ... memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition and ... fast results , By focusing on low weight loads ...
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... and Drug Administration will have many restaurant chains posting calorie ... movie theater popcorn and ice cream parlor fare. "Americans ... often consuming less nutritious food and underestimating the calories they ... afternoon news conference. Although listing calorie counts on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... the drug Rimonabant (Acomplia) a selective cannabinoid receptor blocker ... . Supplementation with 20 milligrams of rimonabant a day ... waist circumference -- a marker of cardiovascularly dangerous visceral ... the prevalence of metabolic syndrome in overweight/obese patients. ...
... to avoid medical mistakes, but now it seems computerized prescription ... is known that adverse drug events injure or kill more ... are trying to cut back on that number is with ... use of computerized systems may actually be leading to more ...
... gradually increased recommendations for daily calcium intake, largely from ... to promote healthy bones and prevent osteoporosis. But a ... of milk or other dairy products was not necessarily ... of at least 400 milligrams per day. ,Other ...
... us have not forgotten the thalidomide tragedy thalidomide in the ... morning sickness // to pregnant mothers and resulted in seal ... future use for the infamous medication: helping cancer patients maintain ... in pancreatic cancer patients and was seen to help ...
... cell research that will help in numerous therapies using stem ... human embryonic stem cells in the laboratory. ,Human ... role in regeneration of cells for therapeutic use. However, while ... animal cells and serum and run the risk of being ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
Cached Medicine News:
... Single Use reloadable linear stapler with ... PI™ disposable stapler is designed for use ... healthy internal tissues. The instrument places a ... when using the 30 VASCULAR cartridges) of ...
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... 75 single-use stapler, anastomotic type, is ... transection, and/or the anastomosis of normal, ... ILA™ 75 single-use stapler, anastomotic type, ... resection, transection, and/or the anastomosis of ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
Medicine Products: